71056-58-1

Usage

Uses

Used in Pharmaceutical Industry:
Ethyl 5-amino-1-methyl-1H-indole-2-carboxylate is used as a synthetic intermediate for the production of pharmaceuticals and organic compounds. Its versatile structure allows for the creation of new chemical entities with potential biological activity, making it a valuable building block in drug development.
Used in Medicinal Chemistry:
Ethyl 5-amino-1-methyl-1H-indole-2-carboxylate is used as a versatile building block in medicinal chemistry for creating new chemical entities with potential biological activity. Its ability to modulate enzyme activity and protein-protein interactions makes it a valuable tool in the development of new drugs and therapies.
Used in Biomedical Research:
Ethyl 5-amino-1-methyl-1H-indole-2-carboxylate is used as a valuable tool in biomedical research for modulating enzyme activity and protein-protein interactions. Its unique structure and properties make it useful in the study of various biological processes and the development of new therapeutic approaches.

InChI:InChI=1/C12H14N2O2/c1-3-16-12(15)11-7-8-6-9(13)4-5-10(8)14(11)2/h4-7H,3,13H2,1-2H3

Upstream product

• 71056-57-0 ethyl 1-methyl-5-nitro-1H-indole-2-carboxylate 

Downstream Products

• 294174-60-0 5-{4-[bis-(2-chloro-ethyl)-amino]-benzoylamino}-1-methyl-1H-indole-2-carboxylic acid ethyl ester 
• 481659-93-2 ethyl 1-methyl-5-[4'-(trifluoromethyl)[1,1'-biphenyl]-2-carboxamido]-1H-indole-2-carboxylate 
• 481660-07-5 5-(2-Acetoxy-benzoylamino)-1-methyl-1H-indole-2-carboxylic Acid Ethyl Ester 
• 167479-53-0 ethyl-5-benzamido-1-methyl-2-indolecarboxylate 
• 167478-27-5 5-benzamido-1-methyl-2-indoloylguanidine hydrochloride 
• 1314128-00-1 ethyl 1-methyl-5-({[4-(tetrahydrofuran-3-ylmethoxy)phenyl]carbonyl}amino)-1H-indole-2-carboxylate 
• 1314128-02-3 ethyl 5-[({2-fluoro-4-[(2S)-tetrahydrofuran-2-ylmethoxy]phenyl}carbonyl)amino]-1-methyl-1H-indole-2-carboxylate 
• 1314127-98-4 ethyl 1-methyl-5-[({4-[(2S)-tetrahydrofuran-2-ylmethoxy]phenyl}carbonyl)amino]-1H-indole-2-carboxylate 
• 1314127-94-0 ethyl 5-({[4-(cyclopropylmethoxy)phenyl]carbonyl}amino)-1-methyl-1H-indole-2-carboxylate 
• 1314126-85-6 4-(cyclopropylmethoxy)-N-[1-methyl-2-({[(2S)-tetrahydrofuran-2-ylmethyl]amino}methyl)-1H-indol-5-yl]benzamide 
• 1314126-84-5 4-(cyclopropylmethoxy)-N-[1-methyl-2-({[(2R)-tetrahydrofuran-2-ylmethyl]amino}methyl)-1H-indol-5-yl]benzamide 
• 1314126-83-4 N-[2-({[2-(acetylamino)ethyl]amino}methyl)-1-methyl-1H-indol-5-yl]-4-(cyclopropylmethoxy)benzamide 
• 1314126-81-2 4-(cyclopropylmethoxy)-N-[1-methyl-2-({[2-methyl-2-(methylsulfonyl)propyl]amino)methyl)-1H-indol-5-yl]benzamide 
• 1314126-80-1 4-(cyclopropylmethoxy)-N-(2-{[(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)amino]methyl}-1-methyl-1H-indol-5-yl)benzamide 

Relevant academic research and scientific papers

1-(CYCLOALKYL-CARBONYL)PROLINE DERIVATIVE

A compound represented by formula (1) (in the formula: ring-D represents a three- to eight-membered hydrocarbon ring; Ra represents an optionally substituted amino C1-6 alkyl group or the like; Rb1 and Rb2 each independently represent a hydrogen atom, a halogen atom, or the like; Rc represents an optionally substituted C6-10 aryl group or the like; Rd represents a hydrogen atom or the like; and ring-Q represents a (hetero)aryl group or the like which may be substituted with a carboxyl group or the like) or a pharmaceutically acceptable salt thereof exhibits an excellent FXIa inhibitory activity, and is useful as a therapeutic agent against thrombosis or the like.

Triamide-substituted heterobicyclic compounds

The invention relates to triamide MTP/ApoB inhibitors of the formula 1 wherein R1-R8 are as defined in the specification, as well as pharmaceutical compositions and uses thereof, and processes for preparing the compounds. The compounds of the invention are useful for the treatment of obesity and lipid disorders.

Viral polymerase inhibitors

An isomer, enantiomer, diastereoisomer, or tautomer of a compound, represented by formula I: wherein R1 is selected from: H, haloalkyl, (C1-6)alkyl, (C2-6)alkenyl, (C3-7)cycloalkyl, (C2-6)alkynyl, (C5-7)cycloalkenyl, 6 or 10-membered aryl, Het all optionally substituted; R2 is selected from (C1-6)alkyl, (C3-7)cycloalkyl, (C6-10)bicycloalkyl, 6- or 10-membered aryl, or Het all optionally substituted; B is N or CR5, wherein R5 is H, halogen, haloalkyl, (C1-6)alkyl, (C3-7)cycloalkyl or (C1-6)alkyl-(C3-7)cycloalkyl; X is N or CR5; D is N or CR5; each of Y1 and Y2 is independently O or S; Z is O, N, or NRz wherein Rz is H, (C1-6)alkyl, (C3-7)cycloalkyl or (C1-6)alkyl-(C3-7)cycloalkyl; R3 and R4 are each independently H, (C1-6)alkyl, first (C3-7)cycloalkyl or 6- or 10-membered aryl, Het (C1-6)alkyl-6- or 10-membered aryl, (C1-6)alkyl-Het; or each R3 and R4 are independently covalently bonded together to form second (C3-7)cycloalkyl, or heterocycle, all optionally substituted; or when Z is N, either R3 or R4 are independently covalently bonded thereto to form a nitrogen-containing heterocycle; R7 is H, (C1-6 alkyl), (C3-7)cycloalkyl or (C1-6)alkyl-(C3-7)cycloalkyl; or R7 is covalently bonded to either of R3 or R4 to form a heterocycle; A is (C1-6) alkyl-CONHR8 wherein R8 is-6- or 10-membered aryl, or Het; or A is a 6- or 10-membered aryl, or Het said aryl or Het being optionally substituted; or a salt or a derivative thereof; such compounds being potent inhibitors of HCV NS5B polymerase.